abbvi look near-term growth eventu
updat forecast estim dec
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research dec
estim dec
price data dec
rate updat dec
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
hold strong portfolio market pipelin
drug increas competit compani key drug humira
slow growth compani total sale
higher portion earn due higher margin revenu
humira key determin perform next
approv rheumatoid arthriti psoriasi crohn
diseas humira hold wide rang indic biosimilar
pressur intern market like lead declin sale
next year expect biosimilar competit
acceler declin also brand competit like
weigh humira growth next sever year particular
new jak inhibitor antibodi repres major
advanc rheumatoid arthriti psoriasi
like lead market share loss humira
well-posit next gener immunolog drug
particular pipelin drug shown improv efficaci safeti
humira current lead treatment option
beyond immunolog cancer drug imbruvica next-biggest
sale contributor imbruvica strong clinic data sever form
blood cancer lead peak sale billion
remain drug larg matur patent expir long
past manufactur specif dose complex
look forward pipelin weight toward new
cancer drug particular pipelin lead
increasingli strong posit blood cancer compani
abl leverag solid entrench imbruvica launch
new drug
beyond intern research develop effort
announc acquisit allergan bring strong cash
flow gener entiti help diversifi compani
away depend humira
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
analyst note earn per share calcul use earn divid share
drug compani strong exposur immunolog
oncolog compani top drug humira repres half
compani current profit compani spun abbott earli
recent announc acquisit allergan add sever new
drug aesthet women health
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
slightli lower fair valu estim
base industri review potenti
litig cost factor discount
cash flow model longer durat allergan
acquisit carri signific premium
stock price view compani under-valued
believ manag opportunist
advantag allergan low price combin need
reduc depend humira model major
annual humira declin begin outsid
 follow key patent settlement
key valuat driver off-set eventu like humira sale
declin compani next-gener immunolog
drug target jak pathway new
pathway seem offer better efficaci improv
side effect profil humira help off-set like
strong blockbust potenti leukemia also compani
sever late-stag cancer drug
help mitig eventu humira sale declin allergan
cash flow also help mitig humira pressur
bottom line next three year expect
improv margin larg driven higher contribut
total sale specialti drug carri high
margin also partnership royalti humira
began expir help improv gross margin
weight averag cost capit use cost
equiti market rate cost debt
medium uncertainti rate key driver compani
valuat humira unknown degre pressur
biosimilar competit humira weigh certainti
addit increas debt exposur need fund
allergan acquisit also weigh firm
uncertainti level lastli ad potenti
 healthcar polici reform relat drug price
bear case creat addit pressur
believ support narrow moat base
patent-protect drug intellectu intang
power salesforc case drug firm
core moat lie portfolio patent-protect
drug howev unlik pharma peer
tend carri wide moat one drug humira repres
major sale profit
greater result emerg brand
competit humira immedi term potenti
gener biosimilar threat time frame
believ excess return like persist year
certain outlook
would need wide-moat rate model
humira sale declin begin rate
declin like gradual typic small
molecule-brand drug face gener competit
complex develop market biosimilar
larg base low volatil cash flow
divers inelast product portfolio rate
uncertainti medium larg line
base-cas fair valu estim bull case
probabl bear case probabl
project fair valu estim rel base case
scenario analysi show moder varianc henc
nevertheless deriv enorm cash flow
current product portfolio fund on-going discoveri
develop next gener drug larg cash
flow creat economi scale enabl
fund averag million requir new drug
strong pharma firm
creat databas intellectu insight help
increas odd success drug develop final
entrench salesforc one
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
roadblock path creat next gener
drug particular fda grown increasingli
risk-sensit approv safe drug drug
highli need area like cancer insur compani
reduc coverag follow-on drug forc drug firm
push true innov reduc power
distribut network lastli govern around world
evalu compar effect program
aggress price negoti increas bar
need futur innov
sought-aft therapeut area immunolog help
firm launch next gener drug make
firm lead candid smaller drug firm need help
develop commerci innov new drug
moat trend neg sever competit
threat target humira new brand drug
launch humira key therapeut area includ
ra psoriasi crohn diseas howev
expect humira lose high degre market share
new drug slow market eros longer term
like addit humira patent
loss like bring new competit threat gener
manufactur damag partli mitig given
biolog complex manufactur market
gener version drug also less power patent
like delay competit case amgen
sever drug compani agre
launch
less-pow patent keep compani bay
addit major industri headwind creat
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
support strong dividend yield
act valuat support cash flow support
dividend look secur next year
increas entrench blood cancer
bode well growth price power remain
solid therapeut area pharmaceut
osever pipelin drug immunolog
mechan action similar drug alreadi
approv take away first mover advantag
oth high profit margin humira like caus
amplifi impact earn sale lost
jak pathway help mitig
oth extra debt need financ allergan deal
could put amplifi pressur core asset
like botox humira face tougher competit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
acquisit allergan significantli increas
debt expect firm net debt posit peak
close billion given strong cash flow
base busi acquir cash flow
allergan deal expect firm rapidli pay
debt still financ dividend howev
expect much room make
signific acquisit sever year capit
tie pay debt fund robust dividend
similar drug firm face risk new
drug failur reimburs challeng new drug
drug price cut larg payer group grow
concentr humira sale make compani
significantli expos new competit threat
humira biosimilar new brand drug
competit also taken signific debt
purchas allergan expect robust cash flow
help manag heavi debt load overal view firm
medium uncertainti level
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
believ manag team demonstr
standard stewardship fail acquisit attempt
shire concern believ new abrupt
treasuri law larg caus acquisit collaps
somewhat give manag pass nevertheless
billion break-up fee relat fail shire deal
show manag gaug polit landscap
correctli billion pharmacycl acquisit
appear fair use capit imbruvica reach
billion plu peak sale project howev billion
acquisit stemcentrx look like miss judgment
key cancer asset appear less effect late-stag
studi importantli mega-acquisit allergan
look like fair use capit help compani
reduc depend humira
turn manag specif led
gonzalez join abbott held mani
manageri post throughout career firm
howev recent led drug group start juli
brief retir rel short tenur
key field drug commerci develop
concern execut go well
leadership howev optimist long-term project
set manag team hurt credibl
ceo/chairman board/
repres date owner name posit common share held report holder issuer
american fund invmt co amer
fidel manag research compani
capit research manag compani
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
launch allergan deal remain track
report third-quart result larg line
expect dont expect major chang
fair valu estim continu view firm
under-valued market like fulli appreci
next-gener immunolog cancer drug howev
despit strength new drug continu
view narrow moat lower wide moat
peer group averag larg due heavi biosimilar
pressur immunolog drug humira next four
quarter total sale increas oper
strong humira sale new product launch
offset intern biosimilar pressur humira
trend continu next two year dont
expect signific pressur top line
 humira biosimilar like launch howev
base strong efficaci expect abbvi next
gener immunolog drug off-set
humira headwind robust recent launch skyrizi
psoriasi rinvoq rheumatoid arthriti gener
million respect drug
launch slightli behind drug similar
mechan action market larg abbvi
like leverag strong formulari entrench
humira gain favor posit new drug
outsid
continu show robust growth expect
continu sever year blood cancer drug imbruvica
venclexta hold lead efficaci competit
threat emerg especi astra calquenc
decemb expect abbvi
entrench hard displac
allergan acquisit remain track
close deal first quarter like follow
divest allergan brazikumab zenpep
competitor abbvi skyrizi creon respect
appeas anti-trust regul
complet review pipelin current
report moat remain secur innov counter
price gener headwind acceler
support acceler growth jul
report second-quart result slightli ahead
consensu expect expect
major chang fair valu base minor
out-performance continu view stock
under-valued market underappreci
compani next-gener drug overli concern
unit state loss exclus immunolog drug
humira anxiou regard leverag taken
allergan acquisit agre
concern believ current valuat take
issu account believ challeng
ahead reflect narrow-moat rate
typic wide-moat rate big pharma
quarter total sale oper
biosimilar pressur weigh intern sale
humira off-set strong sale blood cancer drug
imbruvica expect rate growth larg continu
end howev sale growth
improv intern biosimilar humira
show excel current launch trajectori
upadacitinib like approv later
contribut meaning level late
drug offer signific improv older tnf
immunolog class addit expect traction
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
partial allevi increas
portfolio asset allergan bring particular
view allergan lead product botox well posit
therapeut cosmet set base strong
clinic data power brand power synergi
perspect billion annual save project
manag look reason major stem
research develop well sale
market see allergan presenc women health
particularli help launch endometriosi
blood cancer drug venclexta base increas
indic earlier-lin usag
allergan acquisit remain track
close deal earli expect deal
high
depend humira reason price
expect quickli pay debt also fund
strong dividend project close billion
cumul debt repay two year follow
acquisit significantli de-lever firm short
period time
complet review pipelin current
report moat remain secur innov counter
price gener headwind acceler
abbvi acquisit allergan look opportunist
offer diversif humira jun
narrow-moat announc acquir wide-
moat allergan look like strateg sound deal
reason valuat ad allergan portfolio
brand drug help strengthen moat
partli depend immunolog drug humira
valuat perspect allergan pipelin strong
entrench botox seem fulli factor
stock price believ
opportunist take advantag allergan
valuat look diversifi cash flow away
humira current face intern biosimilar
competit face biosimilar competit
still review detail
acquisit dont expect major chang abbvi
fair valu estim continu view stock
believ increas concern growth
potenti follow humira biosimilar competit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
equival
net properti plant equip
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
